Anti-Human CD262 Recombinant Antibody(Drozitumab)

Name: Anti-Human CD262 Recombinant Antibody(Drozitumab)
Brand: KMD Bioscience
SKU: YR1229

YR1229

科研级 Drozitumab ( 曲齐妥单抗 ), Anti-CD262 Recombinant Antibody, Research Grade Drozitumab

DATASHEET MSDS

Product Description

Alias	科研级 Drozitumab ( 曲齐妥单抗 ), Anti-CD262 Recombinant Antibody, Research Grade Drozitumab
Catalog Number	YR1229
Molecular Name	Drozitumab
Size	1mg, 5mg
Clonity	Monoclonal
Purity	>95% as determined by SDS-PAGE
Concentration	1mg/ml
Antibody Isotype	IgG1 Lambda
Formulation	PBS, pH7.5
Background	Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Drozitumab was developed by Genentech. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.
CAS Number	912628-39-8
Application	ELISA, FCM, IP, FuncS, IF, Neut
Storage Condition	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Remarks	This product is for research use only.
Shipping Condition	Shipped on ice packs.
Target	CD262[Homo sapiens]

Login